Going the distance: Epigenetic regulation of endothelial endothelin-1 controls cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 82, Issue , 2015, Pages 60-62

  Czubryt, Michael P ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BOSENTAN; ENDOTHELIN 1; MESSENGER RNA; MYOCARDIN RELATED TRANSCRIPTION FACTOR A; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TEZOSENTAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CARDIOVASCULAR EFFECT; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONGESTIVE CARDIOMYOPATHY; DNA PACKAGING; DRUG EFFICACY; EDITORIAL; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HEART FAILURE; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; ANIMAL; CARDIOMEGALY; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ANIMALS; CARDIOMEGALY; ENDOTHELIN-1; EPIGENESIS, GENETIC; HUMANS;

EID: 84924769554     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.02.028     Document Type: Editorial

References (36)

1. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
2. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
3. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
4. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265-9269.
5. Bohm F., Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007, 76:8-18.
6. Fukuda Y., Hirata Y., Yoshimi H., Kojima T., Kobayashi Y., Yanagisawa M., et al. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun 1988, 155:167-172.
7. Rakugi H., Nakamaru M., Saito H., Higaki J., Ogihara T. Endothelin inhibits renin release from isolated rat glomeruli. Biochem Biophys Res Commun 1988, 155:1244-1247.
8. Komuro I., Kurihara H., Sugiyama T., Yoshizumi M., Takaku F., Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988, 238:249-252.
9. Uchida Y., Ninomiya H., Saotome M., Nomura A., Ohtsuka M., Yanagisawa M., et al. Endothelin, a novel vasoconstrictor peptide, as potent bronchoconstrictor. Eur J Pharmacol 1988, 154:227-228.
10. Thomas P.B., Liu E.C., Webb M.L., Mukherjee R., Hebbar L., Spinale F.G. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol 1996, 271:H2629-H2637.
11. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Pflugers Arch 1988, 413:108-110.
12. MacCarthy P.A., Grocott-Mason R., Prendergast B.D., Shah A.M. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000, 101:142-147.
13. Ito H., Hirata Y., Hiroe M., Tsujino M., Adachi S., Takamoto T., et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991, 69:209-215.
14. Plumpton C., Ashby M.J., Kuc R.E., O'Reilly G., Davenport A.P. Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) 1996, 90:37-46.
15. Good J.M., Nihoyannopoulos P., Ghatei M.A., Crossman D., Bloom S.R., Clark P., et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II?. Eur Heart J 1994, 15:1634-1640.
16. Yang L.L., Gros R., Kabir M.G., Sadi A., Gotlieb A.I., Husain M., et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 2004, 109:255-261.
17. Mueller E.E., Momen A., Masse S., Zhou Y.Q., Liu J., Backx P.H., et al. Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. Cardiovasc Res 2011, 89:623-633.
18. Matsa L.S., Sagurthi S.R., Ananthapur V., Nalla S., Nallari P. Endothelin 1 gene as a modifier in dilated cardiomyopathy. Gene 2014, 548:256-262.
19. Shohet R.V., Kisanuki Y.Y., Zhao X.S., Siddiquee Z., Franco F., Yanagisawa M. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci U S A 2004, 101:2088-2093.
20. Adiarto S., Heiden S., Vignon-Zellweger N., Nakayama K., Yagi K., Yanagisawa M., et al. ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci 2012, 91:651-657.
21. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355.
22. Mulder P., Richard V., Derumeaux G., Hogie M., Henry J.P., Lallemand F., et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997, 96:1976-1982.
23. Teerlink J.R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?. J Card Fail 2002, 8:124-127.
24. Cleland J.G., Coletta A.P., Freemantle N., Velavan P., Tin L., Clark A.L. Clinical trials update from the American College of Cardiology Meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005, 7:931-936.
25. Kohan D.E., Cleland J.G., Rubin L.J., Theodorescu D., Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?. Life Sci 2012, 91:528-539.
26. Mellin V., Jeng A.Y., Monteil C., Renet S., Henry J.P., Thuillez C., et al. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 2005, 46:390-397.
27. Hong H.J., Chan P., Liu J.C., Juan S.H., Huang M.T., Lin J.G., et al. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004, 61:159-168.
28. Weng X., Yu L., Liang P., Chen D., Cheng X., Yang Y., et al. Endothelial MRTF-A mediates angiotensin II induced cardiac hypertrophy. J Mol Cell Cardiol 2014, 80C:23-33.
29. Yang Y., Cheng X., Tian W., Zhou B., Wu X., Xu H., et al. MRTF-A steers an epigenetic complex to activate endothelin-induced pro-inflammatory transcription in vascular smooth muscle cells. Nucleic Acids Res 2014, 42:10460-10472.
30. Weng X., Yu L., Liang P., Li L., Dai X., Zhou B., et al. A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2015, 10.1016/j.yjmcc.2015.02.010.
31. Conaway J.W. Introduction to theme "Chromatin, epigenetics, and transcription". Annu Rev Biochem 2012, 81:61-64.
32. Trotter K.W., Archer T.K. The BRG1 transcriptional coregulator. Nucl Recept Signal 2008, 6:e004.
33. Greer E.L., Maures T.J., Hauswirth A.G., Green E.M., Leeman D.S., Maro G.S., et al. Members of the H3K4 trimethylation complex regulate lifespan in a germline-dependent manner in C. elegans. Nature 2010, 466:383-387.
34. Czubryt M.P., McAnally J., Fishman G.I., Olson E.N. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A 2003, 100:1711-1716.
35. McKinsey T.A., Olson E.N. Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp 2004, 259:132-141. (discussion 41-5, 63-9).
36. Haldar S.M., McKinsey T.A. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol 2014, 74:98-102.